Characteristics of the studied population
| . | CLPD-NKn = 46) . | Reactive NK (n = 68) . | P . |
|---|---|---|---|
| Age, y, range | 68 (57-77) | 67 (57-77) | NS |
| Sex ratio, M/F [ratio] | 28/18 (1.55) | 42/26 (1.62) | NS |
| Clinical manifestations, n (%) | |||
| Neutropenia | 12 (26) | 16 (24) | NS |
| Autoimmune disorders | 9 (20) | 11 (16) | NS |
| Cutaneous symptoms | 0 (0) | 5 (7) | NS |
| Other hematologic malignancies | 8 (17) | 17 (25) | NS |
| Other solid neoplasia | 1 (2) | 4 (6) | NS |
| Organ transplantation | 0 (0) | 2 (3) | NS |
| Complete blood count | |||
| Hemoglobin, g/dL | 12.5 (10.4-14.2) | 13.0 (11.5-14.5) | NS |
| Platelets, ×109/L | 195 (131-264) | 231 (184-317) | .016 |
| Leukocytes, ×109/L | 10.8 (7.7-10.8) | 7.1 (4.0-9.3) | <.001 |
| Neutrophils, ×109/L | 3.0 (1.2-4.4) | 3.9 (1.8-6.3) | NS |
| NK cells, ×109/L | 2.3 (0.9-3.2) | 0.6 (0.4-0.9) | <.001 |
| FCM clonality assessment at diagnosis, n (%) | |||
| Clonality suspected | 42 (91) | 6 (9) | <.001 |
| Polyclonal | 4 (9) | 62 (91) | |
| Sanger sequencing, n (%) | |||
| STAT3 | 10 (24) | 0 (0) | <.001 |
| . | CLPD-NKn = 46) . | Reactive NK (n = 68) . | P . |
|---|---|---|---|
| Age, y, range | 68 (57-77) | 67 (57-77) | NS |
| Sex ratio, M/F [ratio] | 28/18 (1.55) | 42/26 (1.62) | NS |
| Clinical manifestations, n (%) | |||
| Neutropenia | 12 (26) | 16 (24) | NS |
| Autoimmune disorders | 9 (20) | 11 (16) | NS |
| Cutaneous symptoms | 0 (0) | 5 (7) | NS |
| Other hematologic malignancies | 8 (17) | 17 (25) | NS |
| Other solid neoplasia | 1 (2) | 4 (6) | NS |
| Organ transplantation | 0 (0) | 2 (3) | NS |
| Complete blood count | |||
| Hemoglobin, g/dL | 12.5 (10.4-14.2) | 13.0 (11.5-14.5) | NS |
| Platelets, ×109/L | 195 (131-264) | 231 (184-317) | .016 |
| Leukocytes, ×109/L | 10.8 (7.7-10.8) | 7.1 (4.0-9.3) | <.001 |
| Neutrophils, ×109/L | 3.0 (1.2-4.4) | 3.9 (1.8-6.3) | NS |
| NK cells, ×109/L | 2.3 (0.9-3.2) | 0.6 (0.4-0.9) | <.001 |
| FCM clonality assessment at diagnosis, n (%) | |||
| Clonality suspected | 42 (91) | 6 (9) | <.001 |
| Polyclonal | 4 (9) | 62 (91) | |
| Sanger sequencing, n (%) | |||
| STAT3 | 10 (24) | 0 (0) | <.001 |
Continuous variables are quoted as the median and IQR and categorical variables are quoted as the number of patients and percentage of tested patients. Sanger sequencing data were available for 41 patients in the CLPD-NK group and 45 in the reactive NK-cell proliferation group. NS, not significant.